CDR-609

N/A

Report date: 2025/07/09 11:08:19

Base Information

Drug NameCDR-609

Drug Alias NameCDR-609CDR609

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-Leucine-rich repeat-containing G-protein coupled receptor 5T lymphocytes stimulantsImmunologic cytotoxicity

TargetsLeucine-rich repeat-containing G-protein coupled receptor 5

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCDR-Life Inc

China Registration ClassN/A

Develop Information

Active CompaniesCDR-Life Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A